4.9.3Segment

Contract Development & Manufacturing (CDMO)

Contract manufacturers producing API, drug products, biologics, and sterile injectables for pharmaceutical sponsors.

4
Verticals

Overview

Contract Development & Manufacturing (CDMO) covers contract manufacturers producing APIs, drug products, biologics, and sterile injectables for pharmaceutical sponsors. It is a fast-growing outsourcing market driven by the outsourcing of complex manufacturing, with Catalent (acquired by Novo Holdings), Lonza, Thermo Fisher, and Samsung Biologics among the leaders.

Demand is propelled by biologics and sterile-injectable growth, capacity constraints, and supply-chain-resilience concerns (including reshoring). It is capital-intensive and consolidating, with biologics and advanced-modality capacity the highest-value, most sought-after capabilities.

Market snapshot

FragmentationConsolidatingEstimate

Within pharmaceutical manufacturing (NAICS 325412); CDMOs are not separately identified, so the segment is not separately sized by the Census Bureau.

Business model & economics

Revenue model

Development and manufacturing fees on contracted capacity

Key economics

Recurring revenue
High

multi-year manufacturing contracts

EBITDA margin
20–30%
Capex intensity
High

Characteristics

  • Fast-growing outsourcing of complex manufacturing.
  • Biologics and sterile injectables drive demand.
  • Capacity, resilience, and reshoring concerns.

Geographic concentration

AlabamaAlaskaArizonaFloridaGeorgiaIndianaKansasMaineMinnesotaNorth CarolinaNorth DakotaOklahomaPennsylvaniaSouth DakotaTexasWyomingConnecticutMissouriWest VirginiaIllinoisNew MexicoArkansasCaliforniaDelawareDistrict of ColumbiaHawaiiIowaKentuckyMarylandMichiganMississippiMontanaNew HampshireNew YorkOhioOregonTennesseeUtahVirginiaWashingtonWisconsinNebraskaSouth CarolinaIdahoNevadaVermontLouisianaRhode IslandColoradoMassachusettsNew Jersey

CDMO capacity concentrates in the pharma manufacturing belt across New Jersey and Massachusetts, with a growing Colorado bioprocessing cluster.

New JerseyMassachusettsColorado

U.S. Census Bureau, 2022 Statistics of U.S. Businesses (firms by state), NAICS 325412. Concentration shown by location quotient.

M&A deal context

Deal activityHigh

Who’s acquiring

  • CDMO majors & strategics
  • Pharma-services consolidators
  • PE-backed manufacturing platforms

What’s driving deals

  • Acquisition of biologics and advanced-modality capacity.
  • Biologics and sterile-injectable demand.
  • Supply-chain resilience and reshoring.

Verticals in this segment

Find Contract Development & Manufacturing (CDMO) acquisition targets

Search Acquisera’s index for companies classified under Contract Development & Manufacturing (CDMO) (4.9.3) and build a targeted deal pipeline.

Search companies